Clinical Trial Detail

NCT ID NCT03914612
Title Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
Recruitment Suspended
Gender female
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

endometrial carcinoma

endometrial adenocarcinoma

uterine corpus serous adenocarcinoma

endometrial mixed adenocarcinoma

endometrial clear cell adenocarcinoma

Therapies

Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab

Carboplatin + Paclitaxel

Age Groups: adult senior

No variant requirements are available.